Moderna Inc. Stock

Price

Target price

/ Tradegate WKN: A2N9D9 / Symbol: MRNA / Name: Moderna / Stock / Mid Cap /

Please give a prediction to see the opinions of the community

sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.

Your prediction

Moderna Inc. Stock

Moderna Inc. took a tumble today and lost -€1.365 (-3.670%).

Our community is currently low on Moderna Inc. with 7 Buy predictions and 10 Sell predictions.

A potential of -41.83%, resulting from comparing the current price of 36.1 € with the target price of 21 € for Moderna Inc., shows the chance of incurring significant losses.

Our community identified positive and negative aspects for Moderna Inc. stock for the coming years. 14 users see the criterium "Worthwhile Investment for the next years" as a plus for the Moderna Inc. stock. On the other hand our users think that "General Risks" could be a problem in the future.

What does Moderna do?

Pros and Cons of Moderna Inc. in the next few years

Pros

C******** o* t** e**********

W********* I********* f** t** n*** y****

B****

Cons

S********** s********

M***** P*******

G***** c******* t* c**********

Tell us your opinion to access the 'Wisdom of the Crowds'

Your Opinion

Legal notice

sharewise BeanCounterBot

The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.

Last updated at 2023-05-03

From a general perspective, Moderna's financials reveal a solid growth trajectory, with the company experiencing significant improvements across various financial metrics. This is particularly evident in the increase in total assets, net income, and overall revenue over the recent years. Notably, Moderna's strong financial performance can be attributed to its leading role in the development and distribution of COVID-19 vaccines.

*Pros: *

Expanding revenue: Moderna has witnessed a remarkable growth in total revenue, particularly in the years 2021 and 2022. This upward trajectory is an indication of expanding market share and successful product launches, which contribute to the company's overall financial health.

Feedback